|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSTD1 |
Gene summary for TSTD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSTD1 | Gene ID | 100131187 |
| Gene name | thiosulfate sulfurtransferase like domain containing 1 | |
| Gene Alias | KAT | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006790 | UniProtAcc | Q8NFU3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100131187 | TSTD1 | Dong_P5 | Human | Prostate | Tumor | 2.41e-10 | 1.74e-01 | 0.053 |
| 100131187 | TSTD1 | Dong_P6 | Human | Prostate | Tumor | 3.14e-02 | 2.87e-01 | 0.0371 |
| 100131187 | TSTD1 | P7 | Human | Prostate | Tumor | 9.45e-07 | 6.12e-01 | -0.1025 |
| 100131187 | TSTD1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 2.73e-05 | -2.43e-01 | 0.1575 |
| 100131187 | TSTD1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 3.97e-16 | -5.53e-01 | 0.1545 |
| 100131187 | TSTD1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 4.85e-09 | -5.31e-01 | 0.1569 |
| 100131187 | TSTD1 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 4.72e-03 | -3.72e-01 | 0.1541 |
| 100131187 | TSTD1 | P4_S8_cSCC | Human | Skin | cSCC | 2.88e-12 | 4.01e-01 | -0.3095 |
| 100131187 | TSTD1 | P5_S10_cSCC | Human | Skin | cSCC | 8.54e-07 | 2.49e-01 | -0.299 |
| 100131187 | TSTD1 | P1_cSCC | Human | Skin | cSCC | 5.61e-53 | 1.54e+00 | 0.0292 |
| 100131187 | TSTD1 | P2_cSCC | Human | Skin | cSCC | 6.37e-45 | 1.13e+00 | -0.024 |
| 100131187 | TSTD1 | P4_cSCC | Human | Skin | cSCC | 4.85e-40 | 9.08e-01 | -0.00290000000000005 |
| 100131187 | TSTD1 | P10_cSCC | Human | Skin | cSCC | 7.27e-46 | 1.40e+00 | 0.1017 |
| 100131187 | TSTD1 | cSCC_p1 | Human | Skin | cSCC | 3.06e-03 | 3.04e-01 | -0.1916 |
| 100131187 | TSTD1 | cSCC_p10 | Human | Skin | cSCC | 1.06e-16 | 5.46e-01 | -0.2095 |
| 100131187 | TSTD1 | cSCC_p11 | Human | Skin | cSCC | 1.29e-07 | 3.93e-01 | -0.2102 |
| 100131187 | TSTD1 | cSCC_p4 | Human | Skin | cSCC | 5.92e-15 | 4.32e-01 | -0.2022 |
| 100131187 | TSTD1 | cSCC_p6 | Human | Skin | cSCC | 4.72e-04 | 1.83e-01 | -0.1989 |
| 100131187 | TSTD1 | cSCC_p8 | Human | Skin | cSCC | 2.75e-22 | 5.15e-01 | -0.1971 |
| 100131187 | TSTD1 | cSCC_p9 | Human | Skin | cSCC | 1.07e-16 | 4.39e-01 | -0.1991 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
| GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:000679011 | Liver | Cirrhotic | sulfur compound metabolic process | 129/4634 | 339/18723 | 3.06e-08 | 1.04e-06 | 129 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
| GO:00067903 | Stomach | GC | sulfur compound metabolic process | 35/1159 | 339/18723 | 2.10e-03 | 2.10e-02 | 35 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSTD1 | insertion | In_Frame_Ins | novel | c.150_151insAGAGAC | p.Ser50_Ala51insArgAsp | p.S50_A51insRD | Q8NFU3 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| TSTD1 | insertion | Frame_Shift_Ins | novel | c.148_149insATTTTTTGTATTTTTTTTTA | p.Ser50AsnfsTer80 | p.S50Nfs*80 | Q8NFU3 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| TSTD1 | SNV | Missense_Mutation | c.310G>A | p.Ala104Thr | p.A104T | Q8NFU3 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TSTD1 | SNV | Missense_Mutation | c.197A>G | p.Glu66Gly | p.E66G | Q8NFU3 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TSTD1 | SNV | Missense_Mutation | novel | c.314N>T | p.Gly105Val | p.G105V | Q8NFU3 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TSTD1 | SNV | Missense_Mutation | novel | c.130C>T | p.Pro44Ser | p.P44S | Q8NFU3 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-G3-AAV7-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |